Drugs

Insys Therapeutics to Present at 10th Annual Wells Fargo Healthcare Conference

PHOENIX, AZ: ...

Advaxis Announces Licensing Agreement With Knight Therapeutics and Raises $25 Million Through Direct Investments From Knight and Sectoral Asset Management

PRINCETON, NEW JERSEY and MONTREAL, QUEBEC: Licensing agreement provides Knight commercial rights in Canada to Advaxis's product portfolio including axalimogene filolisbac (ADXS-HPV), ADXS-PSA and ADXS-HER2 Advaxis is eligible to receive u ...

NEMO Ascends to New High Water Mark for Knight

MONTREAL, CANADA: ...

Insys Therapeutics'' Dronabinol Oral Solution NDA Accepted for Filing by FDA

PHOENIX, AZ: April 1, 2016 PDUFA Approval Expected ...

Knight Reports Second Quarter 2015 Results

MONTREAL, QUEBEC: ...

GSK Receives Approval for BREO(R) ELLIPTA(R) for the Treatment of Adults With Asthma

LONDON, UNITED KINGDOM and SOUTH SAN FRANCISCO, CA: ...

Insys Therapeutics Reports Second Quarter 2015 Results

PHOENIX, AZ: ...

Corcept Therapeutics Announces Second Quarter 2015 Results and Provides Corporate Update

MENLO PARK, CA: ...

Insys Therapeutics Receives FDA Orphan Drug Designation for Its Pharmaceutical Cannabidiol for the Treatment of Infantile Spasms

PHOENIX, AZ: ...

The Peace Naturals Project Receives First MMPR Cannabis Oil Licence to Be Issued by Health Canada Under Section 56 Exemption

STAYNER, ONTARIO: ...